Individual Treatment Effect (ITE) estimation is to evaluate the causal effects of treatment strategies on some important outcomes, which is a crucial problem in healthcare. Most existing ITE estimation methods are designed for centralized settings. However, in real-world clinical scenarios, the raw data are usually not shareable among hospitals due to the potential privacy and security risks, which makes the methods not applicable. In this work, we study the ITE estimation task in a federated setting, which allows us to harness the decentralized data from multiple hospitals. Due to the unavoidable confounding bias in the collected data, a model directly learned from it would be inaccurate. One well-known solution is Inverse Probability Treatment Weighting (IPTW), which uses the conditional probability of treatment given the covariates to re-weight each training example. Applying IPTW in a federated setting, however, is non-trivial. We found that even with a well-estimated conditional probability, the local model training step using each hospital's data alone would still suffer from confounding bias. To address this, we propose FED-IPTW, a novel algorithm to extend IPTW into a federated setting that enforces both global (over all the data) and local (within each hospital) decorrelation between covariates and treatments. We validated our approach on the task of comparing the treatment effects of mechanical ventilation on improving survival probability for patients with breadth difficulties in the Intensive Care Unit (ICU). We conducted experiments on both synthetic and real-world eICU datasets, and the results show that FED-IPTW outperforms state-of-the-art methods on all the metrics on factual prediction and ITE estimation tasks, paving the way for personalized treatment strategy design in mechanical ventilation usage.

drug discovery. Most existing drug repurposing studies using real-world patient data often treat the entire population as homogeneous, ignoring the heterogeneity of treatment responses across patient subgroups. This approach may overlook promising drugs that benefit specific subgroups but lack notable treatment effects across the entire population, potentially limiting the number of repurposable candidates identified. To address this, we introduce STEDR, a novel drug repurposing framework that integrates subgroup analysis with treatment effect estimation. Our approach first identifies repurposing candidates by emulating multiple clinical trials on real-world patient data and then characterizes patient subgroups by learning subgroup-specific treatment effects. We deploy STEDR to Alzheimer's Disease (AD), a condition with few approved drugs and known heterogeneity in treatment responses. We emulate trials for over one thousand medications on a large-scale real-world database covering over 8 million patients, identifying 14 drug candidates with beneficial effects to AD in characterized subgroups. Experiments demonstrate STEDR's superior capability in identifying repurposing candidates compared to existing approaches. Additionally, our method can characterize clinically relevant patient subgroups associated with important AD-related risk factors, paving the way for precision drug repurposing.

Living environments play a vital role in the prevalence and progression of diseases, and understanding their impact on patient's health status becomes increasingly crucial for developing AI models. However, due to the lack of long-term and fine-grained spatial and temporal data in public and population health studies, most existing studies fail to incorporate environmental data, limiting the models' performance and real-world application. To address this shortage, we developed SatHealth, a novel dataset combining multimodal spatiotemporal data, including environmental data, satellite images, all-disease prevalences estimated from medical claims, and social determinants of health (SDoH) indicators. We conducted experiments under two use cases with SatHealth: regional public health modeling and personal disease risk prediction. Experimental results show that living environmental information can significantly improve AI models' performance and temporal-spatial generalizability on various tasks. Finally, we deploy a web-based application to provide an exploration tool for SatHealth and one-click access to both our data and regional environmental embedding to facilitate plug-and-play utilization. SatHealth is now published with data in Ohio, and we will keep updating SatHealth to cover the other parts of the US. With the web application and published code pipeline, our work provides valuable angles and resources to include environmental data in healthcare research and establishes a foundational framework for future research in environmental health informatics.

., the six-organ dysfunction assessment of SOFA in Figure 1) play a vital role in sepsis identification within clinicians' workflow, providing evidence-based risk assessments essential for sepsis diagnosis. However, artificial intelligence (AI) sepsis prediction models typically generate a single sepsis risk score without incorporating clinical calculators for assessing organ dysfunctions, making the models less convincing and transparent to clinicians. To bridge the gap, we propose to mimic clinicians' workflow with a novel framework SepsisCalc to integrate clinical calculators into the predictive model, yielding a clinically transparent and precise model for utilization in clinical settings. Practically, clinical calculators usually combine information from multiple component variables in Electronic Health Records (EHR), and might not be applicable when the variables are (partially) missing. We mitigate this issue by representing EHRs as temporal graphs and integrating a learning module to dynamically add the accurately estimated calculator to the graphs. Experimental results on real-world datasets show that the proposed model outperforms state-of-the-art methods on sepsis prediction tasks. Moreover, we developed a system to identify organ dysfunctions and potential sepsis risks, providing a human-AI interaction tool for deployment, which can help clinicians understand the prediction outputs and prepare timely interventions for the corresponding dysfunctions, paving the way for actionable clinical decision-making support for early intervention.

Precise estimation of treatment effects is crucial for accurately evaluating the intervention. While deep learning models have exhibited promising performance in learning counterfactual representations for treatment effect estimation (TEE), a major limitation in most of these models is that they often overlook the diversity of treatment effects across potential subgroups that have varying treatment effects and characteristics, treating the entire population as a homogeneous group. This limitation restricts the ability to precisely estimate treatment effects and provide targeted treatment recommendations. In this paper, we propose a novel treatment effect estimation model, named SubgroupTE, which incorporates subgroup identification in TEE. SubgroupTE identifies heterogeneous subgroups with different responses and more precisely estimates treatment effects by considering subgroup-specific treatment effects in the estimation process. In addition, we introduce an expectation-maximization (EM)-based training process that iteratively optimizes estimation and subgrouping networks to improve both estimation and subgroup identification. Comprehensive experiments on the synthetic and semi-synthetic datasets demonstrate the outstanding performance of SubgroupTE compared to the existing works for treatment effect estimation and subgrouping models. Additionally, a real-world study demonstrates the capabilities of SubgroupTE in enhancing targeted treatment recommendations for patients with opioid use disorder (OUD) by incorporating subgroup identification with treatment effect estimation.

Sepsis is the leading cause of in-hospital mortality in the USA. Early sepsis onset prediction and diagnosis could significantly improve the survival of sepsis patients. Existing predictive models are usually trained on high-quality data with few missing information, while missing values widely exist in real-world clinical scenarios (especially in the first hours of admissions to the hospital), which causes a significant decrease in accuracy and an increase in uncertainty for the predictive models. The common method to handle missing values is imputation, which replaces the unavailable variables with estimates from the observed data. The uncertainty of imputation results can be propagated to the sepsis prediction outputs, which have not been studied in existing works on either sepsis prediction or uncertainty quantification. In this study, we first define such propagated uncertainty as the variance of prediction output and then introduce uncertainty propagation methods to quantify the propagated uncertainty. Moreover, for the potential high-risk patients with low confidence due to limited observations, we propose a robust active sensing algorithm to increase confidence by actively recommending clinicians to observe the most informative variables. We validate the proposed models in both publicly available data (i.e., MIMIC-III and AmsterdamUMCdb) and proprietary data in The Ohio State University Wexner Medical Center (OSUWMC). The experimental results show that the propagated uncertainty is dominant at the beginning of admissions to hospitals and the proposed algorithm outperforms state-of-the-art active sensing methods. Finally, we implement a SepsisLab system for early sepsis prediction and active sensing based on our pre-trained models. Clinicians and potential sepsis patients can benefit from the system in early prediction and diagnosis of sepsis.

Deep learning models have demonstrated promising results in estimating treatment effects (TEE). However, most of them overlook the variations in treatment outcomes among subgroups with distinct characteristics. This limitation hinders their ability to provide accurate estimations and treatment recommendations for specific subgroups. In this study, we introduce a novel neural network-based framework, named SubgroupTE, which incorporates subgroup identification and treatment effect estimation. SubgroupTE identifies diverse subgroups and simultaneously estimates treatment effects for each subgroup, improving the treatment effect estimation by considering the heterogeneity of treatment responses. Comparative experiments on synthetic data show that SubgroupTE outperforms existing models in treatment effect estimation. Furthermore, experiments on a real-world dataset related to opioid use disorder (OUD) demonstrate the potential of our approach to enhance personalized treatment recommendations for OUD patients.

Sleep staging is a key challenge in diagnosing and treating sleep-related diseases due to its labor-intensive, time-consuming, costly, and error-prone. With the availability of large-scale sleep signal data, many deep learning methods are proposed for automatic sleep staging. However, these existing methods face several challenges including the heterogeneity of patients’ underlying health conditions and the difficulty modeling complex interactions between sleep stages. In this paper, we propose a neural network architecture named DREAM to tackle these issues for automatic sleep staging. DREAM consists of (i) a feature representation network that generates robust representations for sleep signals via the variational auto-encoder framework and contrastive learning and (ii) a sleep stage classification network that explicitly models the interactions between sleep stages in the sequential context at both feature representation and label classification levels via Transformer and conditional random field architectures. Our experimental results indicate that DREAM significantly outperforms existing methods for automatic sleep staging on three sleep signal datasets.

Despite intense efforts in basic and clinical research, an individualized ventilation strategy for critically ill patients remains a major challenge. Recently, dynamic treatment regime (DTR) with reinforcement learning (RL) on electronic health records (EHR) has attracted interest from both the healthcare industry and machine learning research community. However, most learned DTR policies might be biased due to the existence of confounders. Although some treatment actions non-survivors received may be helpful, if confounders cause the mortality, the training of RL models guided by long-term outcomes (e.g., 90-day mortality) would punish those treatment actions causing the learned DTR policies to be suboptimal. In this study, we develop a new deconfounding actor-critic network (DAC) to learn optimal DTR policies for patients. To alleviate confounding issues, we incorporate a patient resampling module and a confounding balance module into our actor-critic framework. To avoid punishing the effective treatment actions non-survivors received, we design a short-term reward to capture patients' immediate health state changes. Combining short-term with long-term rewards could further improve the model performance. Moreover, we introduce a policy adaptation method to successfully transfer the learned model to new-source small-scale datasets. The experimental results on one semi-synthetic and two different real-world datasets show the proposed model outperforms the state-of-the-art models. The proposed model provides individualized treatment decisions for mechanical ventilation that could improve patient outcomes.

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in developed countries. Identifying patients at high risk of progression to late AMD, the sight-threatening stage, is critical for clinical actions, including medical interventions and timely monitoring. Recently, deep-learning-based models have been developed and achieved superior performance for late AMD prediction. However, most existing methods are limited to the color fundus photography (CFP) from the last ophthalmic visit and do not include the longitudinal CFP history and AMD progression during the previous years' visits. Patients in different AMD subphenotypes might have various speeds of progression in different stages of AMD disease. Capturing the progression information during the previous years' visits might be useful for the prediction of AMD progression. In this work, we propose a C ontrastive-A ttention-based T ime-aware L ong S hort-T erm M emory network (CAT-LSTM ) to predict AMD progression. First, we adopt a convolutional neural network (CNN) model with a contrastive attention module (CA) to extract abnormal features from CFPs. Then we utilize a time-aware LSTM (T-LSTM) to model the patients' history and consider the AMD progression information. The combination of disease progression, genotype information, demographics, and CFP features are sent to T-LSTM. Moreover, we leverage an auto-encoder to represent temporal CFP sequences as fixed-size vectors and adopt k-means to cluster them into subphenotypes. We evaluate the proposed model based on real-world datasets, and the results show that the proposed model could achieve 0.925 on area under the receiver operating characteristic (AUROC) for 5-year late-AMD prediction and outperforms the state-of-the-art methods by more than 3%, which demonstrates the effectiveness of the proposed CAT-LSTM. After analyzing patient representation learned by an auto-encoder, we identify 3 novel subphenotypes of AMD patients with different characteristics and progression rates to late AMD, paving the way for improved personalization of AMD management. The code of CAT-LSTM can be found at https://github.com/yinchangchang/CAT-LSTM .

molecular design is a key challenge in drug discovery due to the complexity of chemical space. With the availability of molecular datasets and advances in machine learning, many deep generative models are proposed for generating novel molecules with desired properties. However, most of the existing models focus only on molecular distribution learning and target-based molecular design, thereby hindering their potentials in real-world applications. In drug discovery, phenotypic molecular design has advantages over target-based molecular design, especially in first-in-class drug discovery. In this work, we propose the first deep graph generative model (FAME) targeting phenotypic molecular design, in particular gene expression-based molecular design. FAME leverages a conditional variational autoencoder framework to learn the conditional distribution generating molecules from gene expression profiles. However, this distribution is difficult to learn due to the complexity of the molecular space and the noisy phenomenon in gene expression data. To tackle these issues, a gene expression denoising (GED) model that employs contrastive objective function is first proposed to reduce noise from gene expression data. FAME is then designed to treat molecules as the sequences of fragments and learn to generate these fragments in autoregressive manner. By leveraging this fragment-based generation strategy and the denoised gene expression profiles, FAME can generate novel molecules with a high validity rate and desired biological activity. The experimental results show that FAME outperforms existing methods including both SMILES-based and graph-based deep generative models for phenotypic molecular design. Furthermore, the effective mechanism for reducing noise in gene expression data proposed in our study can be applied to omics data modeling in general for facilitating phenotypic drug discovery.

Complication risk profiling is a key challenge in the healthcare domain due to the complex interaction between heterogeneous entities (e.g., visit, disease, medication) in clinical data. With the availability of real-world clinical data such as electronic health records and insurance claims, many deep learning methods are proposed for complication risk profiling. However, these existing methods face two open challenges. First, data heterogeneity relates to those methods leveraging clinical data from a single view only while the data can be considered from multiple views (e.g., sequence of clinical visits, set of clinical features). Second, generalized prediction relates to most of those methods focusing on single-task learning, whereas each complication onset is predicted independently, leading to suboptimal models. We propose a multi-view multi-task network (MuViTaNet) for predicting the onset of multiple complications to tackle these issues. In particular, MuViTaNet complements patient representation by using a multi-view encoder to effectively extract information by considering clinical data as both sequences of clinical visits and sets of clinical features. In addition, it leverages additional information from both related labeled and unlabeled datasets to generate more generalized representations by using a new multi-task learning scheme for making more accurate predictions. The experimental results show that MuViTaNet outperforms existing methods for profiling the development of cardiac complications in breast cancer survivors. Furthermore, thanks to its multi-view multi-task architecture, MuViTaNet also provides an effective mechanism for interpreting its predictions in multiple perspectives, thereby helping clinicians discover the underlying mechanism triggering the onset and for making better clinical treatments in real-world scenarios.

Disease progression modeling (DPM) involves using mathematical frameworks to quantitatively measure the severity of how certain disease progresses. DPM is useful in many ways such as predicting health state, categorizing disease stages, and assessing patients’ disease trajectory, etc. Recently, with the wider availability of electronic health records (EHR) and the broad application of data-driven machine learning methods, DPM has attracted much attention yet remains two major challenges: (i) Due to the existence of irregularity, heterogeneity, and long-term dependency in EHRs, most existing DPM methods might not be able to provide comprehensive patient representations. (ii) Lots of records in EHRs might be irrelevant to the target disease. Most existing models learn to automatically focus on the relevant information instead of explicitly capture the target-relevant events, which might make the learned model suboptimal. To address these two issues, we propose Temporal Clustering with External Memory Network (TC-EMNet) for DPM that groups patients with similar trajectories to form disease clusters/stages. TC-EMNet uses a variational autoencoder (VAE) to capture internal complexity from the input data and utilizes an external memory work to capture long-term distance information, both of which are helpful for producing comprehensive patient health states. Last but not least, the k-means algorithm is adopted to cluster the extracted comprehensive patient representation to capture disease progression. Experiments on two real-world datasets show that our model demonstrates competitive clustering performance against state-of-the-art methods and is able to identify clinically meaningful clusters. The visualization of the patient representations shows that the proposed model can generate better patient health states than the baselines.

Estimating the individual treatment effect (ITE) from observational data is meaningful and practical in healthcare. Existing work mainly relies on the strong ignorability assumption that no hidden confounders exist, which may lead to bias in estimating causal effects. Some studies considering the hidden confounders are designed for static environment and not easily adaptable to a dynamic setting. In fact, most observational data (e.g., electronic medical records) is naturally dynamic and consists of sequential information. In this paper, we propose Deep Sequential Weighting (DSW) for estimating ITE with time-varying confounders. Specifically, DSW infers the hidden confounders by incorporating the current treatment assignments and historical information using a deep recurrent weighting neural network. The learned representations of hidden confounders combined with current observed data are leveraged for potential outcome and treatment predictions. We compute the time-varying inverse probabilities of treatment for re-weighting the population. We conduct comprehensive comparison experiments on fully-synthetic, semi-synthetic and real-world datasets to evaluate the performance of our model and baselines. Results demonstrate that our model can generate unbiased and accurate treatment effect by conditioning both time-varying observed and hidden confounders, paving the way for personalized medicine.

Sepsis is a heterogeneous clinical syndrome that is the leading cause of mortality in hospital intensive care units (ICUs). Identification of sepsis subphenotypes may allow for more precise treatments and lead to more targeted clinical interventions. Recently, sepsis subtyping on electronic health records (EHRs) has attracted interest from healthcare researchers. However, most sepsis subtyping studies ignore the temporality of EHR data and suffer from missing values. In this paper, we propose a new sepsis subtyping framework to address the two issues. Our subtyping framework consists of a novel Time-Aware Multi-modal auto-Encoder (TAME) model which introduces time-aware attention mechanism and incorporates multi-modal inputs (e.g., demographics, diagnoses, medications, lab tests and vital signs) to impute missing values, a dynamic time wrapping (DTW) method to measure patients' temporal similarity based on the imputed EHR data, and a weighted k-means algorithm to cluster patients. Comprehensive experiments on real-world datasets show TAME outperforms the baselines on imputation accuracy. After analyzing TAME-imputed EHR data, we identify four novel subphenotypes of sepsis patients, paving the way for improved personalization of sepsis management.

Due to their promising performance in clinical risk prediction with Electronic Health Records (EHRs), deep learning methods have attracted significant interest from healthcare researchers. However, there are 4 challenges: (i) Data insufficiency. Many methods require large amounts of training data to achieve satisfactory results. (ii) Interpretability. Results from many methods are hard to explain to clinicians (e.g., why the models make particular predictions and which events cause clinical outcomes). (iii) Domain knowledge integration. No existing method dynamically exploits complicated medical knowledge (e.g., relations such as cause and is-caused-by between clinical events). (iv) Time interval information. Most existing methods only consider the relative order of visits from EHRs, but ignore the irregular time intervals between neighboring visits. In the study, we propose a new model, Domain Knowledge Guided Recurrent Neural Networks (DG-RNN), by directly introducing domain knowledge from the medical knowledge graph into an RNN architecture, as well as taking the irregular time intervals into account. Experimental results on heart failure risk prediction tasks show that our model not only outperforms state-of-the-art deep-learning based risk prediction models, but also associates individual medical events with heart failure onset, thus paving the way for interpretable accurate clinical risk predictions.

In contrast to the one-size-fits-all approach to medicine, precision medicine will allow targeted prescriptions based on the specific profile of the patient thereby avoiding adverse reactions and ineffective but expensive treatments. Longitudinal observational data such as Electronic Health Records (EHRs) have become an emerging data source for personalized medicine. In this paper, we propose a unified computational framework, called PerDREP, to predict the unique response patterns of each individual patient from EHR data. PerDREP models individual responses of each patient to the drug exposure by introducing a linear system to account for patients' heterogeneity, and incorporates a patient similarity graph as a network regularization. We formulate PerDREP as a convex optimization problem and develop an iterative gradient descent method to solve it. In the experiments, we identify the effect of drugs on Glycated hemoglobin test results. The experimental results provide evidence that the proposed method is not only more accurate than state-of-the-art methods, but is also able to automatically cluster patients into multiple coherent groups, thus paving the way for personalized medicine.

The proliferation of Electronic Health Records (EHRs) challenges data miners to discover potential and previously unknown patterns from a large collection of medical data. One of the tasks that we address in this paper is to reveal previously unknown effects of drugs on laboratory test results. We propose a method that leverages drug information to find a meaningful list of drugs that have an effect on the laboratory result. We formulate the problem as a convex non smooth function and develop a proximal gradient method to optimize it. The model has been evaluated on two important use cases: lowering low-density lipoproteins and glycated hemoglobin test results. The experimental results provide evidence that the proposed method is more accurate than the state-of-the-art method, rediscover drugs that are known to lower the levels of laboratory test results, and most importantly, discover additional potential drugs that may also lower these levels.

Computational Drug Discovery, which uses computational techniques to facilitate and improve the drug discovery process, has aroused considerable interests in recent years. Drug Repositioning (DR) and Drug-Drug Interaction (DDI) prediction are two key problems in drug discovery and many computational techniques have been proposed for them in the last decade. Although these two problems have mostly been researched separately in the past, both DR and DDI can be formulated as the problem of detecting positive interactions between data entities (DR is between drug and disease, and DDI is between pairwise drugs). The challenge in both problems is that we can only observe a very small portion of positive interactions. In this paper, we propose a novel framework called Dyadic Positive-Unlabeled learning (DyPU) to solve the problem of detecting positive interactions. DyPU forces positive data pairs to rank higher than the average score of unlabeled data pairs. Moreover, we also derive the dual formulation of the proposed method with the rectifier scoring function and we show that the associated non-trivial proximal operator admits a closed form solution. Extensive experiments are conducted on real drug data sets and the results show that our method achieves superior performance comparing with the state-of-the-art.

We study the problem of Polyadic Prediction, where the input consists of an ordered tuple of objects, and the goal is to predict a measurement associated with them. Many tasks can be naturally framed as Polyadic Prediction problems. In drug discovery, for instance, it is important to estimate the treatment effect of a drug on various tissue-specific diseases, as it is expressed over the available genes. Thus, we essentially predict the expression value measurements for several (drug, gene, tissue) triads. To tackle Polyadic Prediction problems, we propose a general framework, called Polyadic Regression, predicting measurements associated with multiple objects. Our framework is inductive, in the sense of enabling predictions for new objects, unseen during training. Our model is expressive, exploring high-order, polyadic interactions in an efficient manner. An alternating Proximal Gradient Descent procedure is proposed to fit our model. We perform an extensive evaluation using real-world chemogenomics data, where we illustrate the superior performance of Polyadic Regression over the prior art. Our method achieves an increase of 0.06 and 0.1 in Spearman correlation between the predicted and the actual measurement vectors, for predicting missing polyadic data and predicting polyadic data for new drugs, respectively.

In the last decade, advances in high-throughput technologies, growth of clinical data warehouses, and rapid accumulation of biomedical knowledge provided unprecedented opportunities and challenges to researchers in biomedical informatics. One distinct solution, to efficiently conduct big data analytics for biomedical problems, is the application of matrix computation and factorization methods such as non-negative matrix factorization, joint matrix factorization, tensor factorization. Compared to probabilistic and information theoretic approaches, matrix-based methods are fast, easy to understand and implement. In this tutorial, we provide a review of recent advances in algorithms and methods using matrix and their potential applications in biomedical informatics. We survey various related articles from data mining venues as well as from biomedical informatics venues to share with the audience key problems and trends in matrix computation research, with different novel applications such as drug repositioning, personalized medicine, and electronic phenotyping.

The recent years have witnessed a surge of interests in data analytics with patient Electronic Health Records (EHR). Data-driven healthcare, which aims at effective utilization of big medical data, representing the collective learning in treating hundreds of millions of patients, to provide the best and most personalized care, is believed to be one of the most promising directions for transforming healthcare. EHR is one of the major carriers for make this data-driven healthcare revolution successful. There are many challenges on working directly with EHR, such as temporality, sparsity, noisiness, bias, etc. Thus effective feature extraction, or phenotyping from patient EHRs is a key step before any further applications. In this paper, we propose a deep learning approach for phenotyping from patient EHRs. We first represent the EHRs for every patient as a temporal matrix with time on one dimension and event on the other dimension. Then we build a four-layer convolutional neural network model for extracting phenotypes and perform prediction. The first layer is composed of those EHR matrices. The second layer is a one-side convolution layer that can extract phenotypes from the first layer. The third layer is a max pooling layer introducing sparsity on the detected phenotypes, so that only those significant phenotypes will remain. The fourth layer is a fully connected softmax prediction layer. In order to incorporate the temporal smoothness of the patient EHR, we also investigated three different temporal fusion mechanisms in the model: early fusion, late fusion and slow fusion. Finally the proposed model is validated on a real world EHR data warehouse under the specific scenario of predictive modeling of chronic diseases.

Logistic regression is one core predictive modeling technique that has been used extensively in health and biomedical problems. Recently a lot of research has been focusing on enforcing sparsity on the learned model to enhance its effectiveness and interpretability, which results in sparse logistic regression model. However, no matter the original or sparse logistic regression, they require the inputs to be in vector form. This limits the applicability of logistic regression in the problems when the data cannot be naturally represented vectors (e.g., functional magnetic resonance imaging and electroencephalography signals). To handle the cases when the data are in the form of multi-dimensional arrays, we propose MulSLR: Multilinear Sparse Logistic Regression. MulSLR can be viewed as a high order extension of sparse logistic regression. Instead of solving one classification vector as in conventional logistic regression, we solve for K classification vectors in MulSLR (K is the number of modes in the data). We propose a block proximal descent approach to solve the problem and prove its convergence. The convergence rate of the proposed algorithm is also analyzed. Finally we validate the efficiency and effectiveness of MulSLR on predicting the onset risk of patients with Alzheimer's disease and heart failure.